| Issue Date | Title | Author(s) |
| 2015 | Abiraterone acetate after docetaxel-based chemotherapy failure in Asian patients with metastatic castration-resistant prostate cancer | Ye, Dingwei; Zou, Qing; Sun, Zhongquan; Sun, Yinghao; Li, Changling; Du, Chuanjun; Chen, Zhiwen; Shan, Yuxi; Huang, Yiran; Jin, Jie; Ye, Zhang Qun; Xie, Liping; Feng, Yi; De Porre, Peter; Liu, Weiping; Ye, Dingwei |
| 2015 | Abiraterone acetate after docetaxel-based chemotherapy failure in Asian patients with metastatic castration-resistant prostate cancer | Ye, Dingwei; Zou, Qing; Sun, Zhongquan; Sun, Yinghao; Li, Changling; Du, Chuanjun; Chen, Zhiwen; Shan, Yuxi; Huang, Yiran; Jin, Jie; Ye, Zhang Qun; Xie, Liping; Feng, Yi; De Porre, Peter; Liu, Weiping; Ye, Dingwei |
| 2016 | Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study | Sun, Yinghao; Zou, Qing; Sun, Zhongquan; Li, Changling; Du, Chuanjun; Chen, Zhiwen; Shan, Yuxi; Huang, Yiran; Jin, Jie; Ye, Zhang Qun; Xie, Liping; Lin, Guowen; Feng, Yi; De Porre, Peter; Liu, Weiping; Ye, Dingwei |
| 2015 | Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml | Chen, Rui; Huang, Yiran; Cai, Xiaobing; Xie, Liping; He, Dalin; Zhou, Liqun; Xu, Chuanliang; Gao, Xu; Ren, Shancheng; Wang, Fubo; Ma, Lulin; Wei, Qiang; Yin, Changjun; Tian, Ye; Sun, Zhongquan; Fu, Qiang; Ding, Qiang; Zheng, Junhua; Ye, Zhangqun; Ye, Dingwei; Xu, Danfeng; Hou, Jianquan; Xu, Kexin; Yuan, Jianlin; Gao, Xin; Liu, Chunxiao; Pan, Tiejun; Sun, Yinghao |
| Jul-2021 | The characteristics and risk factors of healthcare-seeking men with lower urinary tract symptoms in China: Initial report from the POInT group | Song, Qi-Xiang; He, Fan; Sun, Xionglin; Liu, Ke; Chen, Zhong; Li, Mingzhao; Lin, Jianhai; Xu, Zhihui; Li, Yan; Zhang, Yaoguang; Huang, Hai; Zhang, Yi; Ye, Xiaofei; Peng, Yonghan; Li, Longkun; Yin, Lei; Gao, Xiaofeng; Song, Bo; Sun, Yinghao; Wang, Jianye; Xue, Wei; Abrams, Paul |
| 2018 | Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance | Zhang, Jinfang; Bu, Xia; Wang, Haizhen; Zhu, Yasheng; Geng, Yan; Nihira, Naoe Taira; Tan, Yuyong; Ci, Yanpeng; Wu, Fei; Dai, Xiangpeng; Guo, Jianping; Huang, Yu-Han; Fan, Caoqi; Ren, Shancheng; Sun, Yinghao; Freeman, Gordon J. .; Sicinski, Piotr; Wei, Wenyi |
| 2016 | Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy | Chen, Rui; Xie, Liping; Xue, Wei; Ye, Zhangqun; Ma, Lulin; Gao, Xu; Ren, Shancheng; Wang, Fubo; Zhao, Lin; Xu, Chuanliang; Sun, Yinghao |
| 2014 | A multicenter, noncontrolled clinical study of sorafenib adjuvant therapy in advanced renal cell carcinoma | Ye, Dingwei; He, Zhisong; Sun, Yinghao; Kong, Chuize; Xie, Liping; Wei, Qiang; Ye, Zhangqun; Li, Min; Shen, Zhoujun; Li, Hanzhong; Sun, Guang; Ma, Jianhui |
| 2017 | Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts | Chen, Rui; Sjoberg, Daniel D.; Huang, Yiran; Xie, Liping; Zhou, Liqun; He, Dalin; Vickers, Andrew J.; Sun, Yinghao |
| 2013 | Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study | Guo, Jun; Huang, Yiran; Zhang, Xu; Zhou, Fangjian; Sun, Yinghao; Qin, Shukui; Ye, Zhangqun; Wang, Hui; Jappe, Annette; Straub, Patrick; Pirotta, Nicoletta; Gogov, Sven |
